Optoceutics ApS

The company's primary activities has been at the forefront of medical research and innovation since 2018, driven by a vision to address neurological and psychiatric diseases. Our primary focus is on targeting electrical signaling deficits in

the brain, with the end goal of developing treatments for conditions such as Alzheimer's disease and dementia.

The results of the company's activities in the financial year amounted to a profit/loss of DKK -8.736.152 against DKK -9.184.625 in last financial year. The equity at the balance sheet date amounted to DKK 32.320.160.

In 2025, Optoceutics Continued significant progress in customer and economic product validation, IP portfolio and product development, and clinical validation.

Despite the challenges of a traditional startup, we remain dedicated to advancing preventative care before symptoms arise. Our journey is marked by innovation, compassion, and a steadfast commitment to excellence. As we look to the future, we pledge to continue delivering on our goals, benefiting patients, families, society, and shareholders. We extend our gratitude to all who have trusted in our vision and team. Thank you for joining us on this journey.

In 2025, Optoceutics expanded its go to market channels to include pilots in government payment and B2B memory care centers. These efforts gave insights into these channels as well as enabled us to perform economic model validation with our customers; we have growing confidence in our ability to make a meaningful difference both in terms of personal impact as evidenced in a growing body of customer testimonials and product feedback as well as health economics measures